[Correspondence] Alternative approaches to risk–benefit balancing in immunotherapy

We read with great interest the Editorial in The Lancet Oncology1 sharing the Editors’ perspectives on the risk–benefit balance of immunotherapies. Although we agree with their viewpoints, we advocate caution in recommending options like prophylactic tocilizumab due to inadequate robust supporting data. Furthermore, we wish to highlight alternative approaches for effective risk optimisation and cost-effectiveness.